1. Home
  2. EVOK vs HOTH Comparison

EVOK vs HOTH Comparison

Compare EVOK & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evoke Pharma Inc.

EVOK

Evoke Pharma Inc.

HOLD

Current Price

$11.00

Market Cap

18.4M

Sector

Health Care

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

18.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVOK
HOTH
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
18.0M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
EVOK
HOTH
Price
$11.00
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
30.4K
219.2K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,424,652.00
N/A
Revenue This Year
$58.96
N/A
Revenue Next Year
$57.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
67.40
N/A
52 Week Low
$1.94
$0.66
52 Week High
$10.99
$3.80

Technical Indicators

Market Signals
Indicator
EVOK
HOTH
Relative Strength Index (RSI) 85.18 35.73
Support Level $10.66 $1.16
Resistance Level $10.99 $1.25
Average True Range (ATR) 0.04 0.06
MACD -0.18 0.00
Stochastic Oscillator 95.00 16.67

Price Performance

Historical Comparison
EVOK
HOTH

About EVOK Evoke Pharma Inc.

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

Share on Social Networks: